Movement disorders, including Parkinson’s, Huntington’s, and multiple sclerosis, present unique challenges for clinical trials, with symptoms that fluctuate across time, setting, and daily activity. While traditional clinician-administered scales remain foundational, they often miss the nuance of a patient’s daily experience.

Digital health technologies (DHTs) offer a powerful, complementary path forward. By capturing motor performance with greater frequency and granularity, both in the clinic and in the real world, we can build a more comprehensive, objective, and longitudinal view of treatment response.

In this session, a panel of experts across clinical development, digital measurement, and research advocacy explore how to effectively integrate digital measures into your CNS trials:

✅ Going Beyond Motor Symptoms: How to capture cognition, sleep, speech, and mood to characterize disease trajectories more effectively.

✅ The Power of Multimodal Data: Strategies for combining sensor-derived measures with established clinical outcome assessments to create a cohesive picture of disease progression.

✅ Defining “Meaningful Evidence”: Best practices for the fit-for-purpose selection and validation of digital components, including usability, analytical validation, and sensitivity to change.

✅ Real-World Integration: Insights into how remote monitoring complements traditional performance-based testing to capture how participants actually function between study visits.

Featured Speakers: 

DIane Stephenson – Vice President, Critical Path Institute (C-Path)

Brett Meyer, PhD – Staff Data Scientist, Sibel Health

Melissa Ceruolo – VP Engineering & Biomarker Analytics, Medidata

Ann Marie Hake, MD, FAAN – Executive Director, Tech@Lilly Digital Health, Eli Lilly and Company

Samantha Volkens – Partnerships Lead, Life Sciences (Moderator), Digital Medicine Society (DiMe)